Top News
Canada
- CIBC reports $1.4B fourth-quarter profit, raises quarterly dividend
- U.S. to require all inbound foreign air passengers to get COVID test the day before
- Ontario?s ?right to disconnect? law has just been passed ? so do you actually have the right to disconnect?
- LifeWorks CEO Stephen Liptrap on why the mental health implications of the pandemic will be with us for another decade
- Shopify sued by publishers accusing company of profiting from textbook piracy
- Most actively traded companies on the Toronto Stock Exchange
- Cargill, union reach tentative deal that could avert strike at High River meat plant
- ?Like a sucker punch?: Canadian travellers rethink holiday plans as Omicron variant spreads
- Calgary?s November home sales up 47 per cent from last year: real estate board
- Trans Mountain pipeline restart ?only a few days away,? says company
International
Technology
Futures
Headlines
- Signet shares jump 4.4% premarket
- Signet now sees FY22 revenue $7.41 bln to $7.49 bln; FactSet consensus $7.2 bln
- Signet now sees Q4 revenue of $2.40 bln to $2.48 bln, FactSet consensus $2.2 bln
- Signet Q3 sales $1.538 bln vs. $1.300 bln a year ago; FactSet consensus $1.427 bln
- : Russell 2000 had dropped in 9 of past 10 sessions, shedding 10.7% over the stretch
- Signet Q3 adj. EPS $1.43; FactSet consensus 72 cents
- Signet Q3 EPS $1.45 vs. 2 cents a year ago
- : iShares Russell 2000 ETF rises 0.9% premarket, after index fell 2.4% Wed. to close at 3 1/2-mo. low
- : Vor Biopharma started at outperform with $30 stock price target at Oppenheimer
- : Okta stock price target cut to $230 from $295 at J.P. Morgan